FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours By Ogkologos - September 2, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-001 and LIBRETTO-121 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 ESMO Announces Results of 2025 Elections June 14, 2025 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung... October 29, 2024 Load more HOT NEWS At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... Alectinib Approved as an Adjuvant Treatment for Lung Cancer Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... What to Know About Navigating Your Cancer Care During An Extreme...
